By. Antonio Passaro, MDDate. October 31, 2023 Antonio Passaro, MD, an oncologist specializing in lung cancer, has been deeply involved in the analysis and interpretation of the Phase 3 MARIPOSA-2 study. The primary objective of this pivotal trial was to investigate the efficacy and safety of the amivantamab regimen, in combination with chemotherapy, for patients … Continue reading Amivantamab: Phase III MARIPOSA-2 combo vs chemotherapy in EGFR-mutated advanced NSCLC